Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from AIM ImmunoTech ( (AIM) ).
On July 28, 2025, AIM ImmunoTech Inc. announced positive data from its ongoing Phase 2 DURIPANC study, which evaluates the combination of its drug Ampligen® with AstraZeneca’s Imfinzi® for treating metastatic pancreatic cancer. The study, a collaboration with AstraZeneca and Erasmus Medical Center, has shown promising results with no significant toxicity and improved progression-free and overall survival rates. This development suggests a potential benefit in combining Ampligen’s selective innate immune activation with durvalumab’s checkpoint inhibition, offering hope for a new therapy in pancreatic cancer maintenance.
The most recent analyst rating on (AIM) stock is a Buy with a $1.00 price target. To see the full list of analyst forecasts on AIM ImmunoTech stock, see the AIM Stock Forecast page.
Spark’s Take on AIM Stock
According to Spark, TipRanks’ AI Analyst, AIM is a Neutral.
The overall stock score for AIM ImmunoTech is driven primarily by its weak financial performance, including persistent losses and negative cash flow, compounded by valuation concerns due to a negative P/E ratio. Technical analysis provides a slightly more neutral view but is not enough to offset the financial concerns. The company’s recent noncompliance notification adds to the risk profile.
To see Spark’s full report on AIM stock, click here.
More about AIM ImmunoTech
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19. The company’s lead product is Ampligen® (rintatolimod), a first-in-class investigational drug with broad spectrum activity in clinical trials for globally important cancers, viral diseases, and disorders of the immune system.
Average Trading Volume: 6,979
Technical Sentiment Signal: Sell
Current Market Cap: $6.42M
For detailed information about AIM stock, go to TipRanks’ Stock Analysis page.